Avadel Pharmaceuticals plc (AVDL) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Avadel Pharmaceuticals plc

AVDL

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

1B

Drug Manufacturers - Specialty & Generic

Next Earning date - 13 Nov 2024

1B

Drug Manufacturers - Specialty & Generic

Next Earning date - 13 Nov 2024

13.22USD

-0.46 ( -3.36%)

Relative Strenght

88

Volume Buzz

-2%

Earning Acce

Yes

Dist 52w H.

31%

Quote Panel

Updated October 24, 2024

1W -2.65 % 1M 4.10 % 3M -18.91 % 1Y 37.03 %

Key Metrics

Market Cap
1.27B
Shares Outstanding
96.27M
Share in Float
90.35M
Dividende
0

Earning Date
13 Nov 2024
Price Target
13.22
Average Volume
916565
Beta
1.632

Range
9.5-19.09
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.avadel.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

13.38x

P/S Ratio

18.08x

P/B Ratio

0.5

Debt/Equity

-111.6%

Net Margin

$-1.1

EPS

How AVDL compares to sector?

P/E Ratio

Relative Strength

AVDL

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$300M

624%

2025-Revenue

$0.56

499%

2025-EPS

$15M

-18%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Rodman & Renshaw

initialise

Previous: Not converted

2024-06-11

Now: Buy

Jefferies

downgrade

Previous: Not converted

2022-08-09

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.33
vs -0.38

Q4.22

N/A

-0.44
vs -0.38

Q1.23

N/A

-0.48
vs -0.45

Q2.23

N/A

-0.70
vs -0.50

Q3.23

N/A

-0.41
vs -0.33

Q4.23

N/A

-0.32
vs -0.44

Q1.24

N/A

-0.30
vs -0.48

Q2.24

N/A

-0.14
vs -0.70

Q3.24

N/A

-0.08
vs -0.41

Q4.24

N/A

-0.02
vs -0.32

Sales Growth

YoY

Current

Estimates

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

1.5M vs NA

Q3.23

NA

7M vs NA

Q4.23

NA

19.5M vs NA

Q1.24

NA

27.2M vs NA

Q2.24

+2674%

41.5M vs 1.5M

Q3.24

+591%

48.4M vs 7M

Q4.24

+188%

56.1M vs 19.5M

Return on Equity

QoQ

Q3.22

+162%

1.62
vs 19.04

Q4.22

+130%

1.3
vs 1.62

Q1.23

+81%

0.81
vs 1.3

Q2.23

-45%

-0.45
vs 0.81

Q3.23

-33%

-0.33
vs -0.45

Q4.23

-33%

-0.33
vs -0.33

Q1.24

-35%

-0.35
vs -0.33

Q2.24

-20%

-0.20
vs -0.35

Institutionnal Ownership

QoQ

Q3.22

83

83
vs 86

-3%

Q4.22

97

97
vs 83

17%

Q1.23

100

100
vs 97

3%

Q2.23

111

111
vs 100

11%

Q3.23

109

109
vs 111

-2%

Q4.23

122

122
vs 109

12%

Q1.24

132

132
vs 122

8%

Q2.24

10

10
vs 132

-92%

Earnings Growth

Latest News

AVDL

globenewswire.com

8 hours ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

AVDL

globenewswire.com

8 hours ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

AVDL

globenewswire.com

9 hours ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

AVDL

zacks.com

10 hours ago

Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz

AVDL

reuters.com

10 hours ago

US FDA expands approval for Avadel's sleep disorder drug

AVDL

seekingalpha.com

12 hours ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

New Feature Coming Soon, Stay Tuned!

Shape

Shape